https://www.businesswire.com/news/home/20260226222582/ja 2026-02-28T20:52:00.000Z weekly 0.5 Business Wire ja PressRelease 2026-02-28T20:52:00.000Z BeOne Medicines、2025年第4四半期および通期決算を発表、BRUKINSAの世界的成功と強固な基盤となるオンコロジー領域でのリーダーシップを強調 688235,06160,ONC https://mms.businesswire.com/media/20260226222582/ja/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260227492966/fr 2026-02-28T17:54:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-02-28T17:54:00.000Z Biocytogen annonce une étape clinique importante avec l'administration du premier traitement à un patient dans le cadre de l'essai de phase 1 sur le TOP1 ADC IDE034, le premier bispécifique B7H3/PTK7 de sa catégorie, développé par IDEAYA 688796,02315 https://mms.businesswire.com/media/20260227492966/fr/2036944/21/Biocytogen_Logo_1080x1080px.jpg https://www.businesswire.com/news/home/20260227171324/it 2026-02-28T17:54:00.000Z weekly 0.5 Business Wire it PressRelease 2026-02-28T17:54:00.000Z Riassunto: Biocytogen annuncia un importante traguardo clinico – trattato il primo paziente nel trial di fase 1 di IDE034, l’ADC TOP1 bispecifico per B7H3/PTK7 “first-in-class” sviluppato da IDEAYA 688796,02315 https://mms.businesswire.com/media/20260227171324/it/2036944/21/Biocytogen_Logo_1080x1080px.jpg https://www.businesswire.com/news/home/20260227717679/es 2026-02-28T17:54:00.000Z weekly 0.5 Business Wire es PressRelease 2026-02-28T17:54:00.000Z Resumen: Biocytogen anuncia un hito clínico con el primer paciente que recibe una dosis en el ensayo fase 1 del primer TOP1 ADC IDE034 biespecífico B7H3/PTK7 en su clase de IDEAYA 688796,02315 https://mms.businesswire.com/media/20260227717679/es/2036944/21/Biocytogen_Logo_1080x1080px.jpg https://www.businesswire.com/news/home/20260227583399/nl 2026-02-28T17:54:00.000Z weekly 0.5 Business Wire nl PressRelease 2026-02-28T17:54:00.000Z Samenvatting: Biocytogen kondigt klinische mijlpaal aan met eerste patiënt die wordt behandeld in fase 1-onderzoek naar IDEAYA's eerste in zijn klasse B7H3/PTK7 bispecifieke TOP1 ADC IDE034 688796,02315 https://mms.businesswire.com/media/20260227583399/nl/2036944/21/Biocytogen_Logo_1080x1080px.jpg https://www.businesswire.com/news/home/20260227781828/de 2026-02-28T17:53:00.000Z weekly 0.5 Business Wire de PressRelease 2026-02-28T17:53:00.000Z Biocytogen verkündet klinischen Meilenstein: Erster Patient in Phase-1-Studie von IDEAYAs erstklassigem B7H3/PTK7-bispezifischen TOP1-ADC IDE034 behandelt 688796,02315 https://mms.businesswire.com/media/20260227781828/de/2036944/21/Biocytogen_Logo_1080x1080px.jpg https://www.businesswire.com/news/home/20260228796958/en/AARD-Investors-Have-Opportunity-to-Join-Aardvark-Therapeutics-Inc.-Fraud-Investigation-With-the-Schall-Law-Firm 2026-02-28T16:46:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T16:46:00.000Z AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm AARD https://mms.businesswire.com/media/20260228796958/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260228266433/pt 2026-02-28T16:15:00.000Z weekly 0.5 Business Wire pt PressRelease 2026-02-28T16:15:00.000Z KnowBe4 lança AIDA Orchestration como o primeiro agente totalmente autônomo para Gestão de Risco Humano https://www.businesswire.com/news/home/20260228159491/es 2026-02-28T16:15:00.000Z weekly 0.5 Business Wire es PressRelease 2026-02-28T16:15:00.000Z KnowBe4 lanza AIDA Orchestration como el primer agente totalmente autónomo para la gestión del riesgo humano https://www.businesswire.com/news/home/20260228025853/en/KEYTRUDA-pembrolizumab-Plus-WELIREG-belzutifan-Given-as-Adjuvant-Therapy-Reduced-the-Risk-of-Disease-Recurrence-or-Death-by-28-Compared-to-KEYTRUDA-Monotherapy-in-Certain-Patients-With-Earlier-Stage-Renal-Cell-Carcinoma-RCC 2026-02-28T15:05:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T15:05:00.000Z KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC) MRK https://mms.businesswire.com/media/20260228025853/en/1106824/21/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg https://www.businesswire.com/news/home/20260228417897/en/WELIREG-belzutifan-Plus-LENVIMA-lenvatinib-Reduced-the-Risk-of-Disease-Progression-or-Death-by-30-Compared-to-Cabozantinib-in-Certain-Previously-Treated-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC 2026-02-28T15:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T15:00:00.000Z WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) MRK https://mms.businesswire.com/media/20260228417897/en/1106824/21/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg https://www.businesswire.com/news/home/20260228505745/en/Berkshire-Hathaway-Inc.-News-Release 2026-02-28T13:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T13:00:00.000Z Berkshire Hathaway Inc. News Release BRK.B,BRK.A https://www.businesswire.com/news/home/20260227334210/en/The-Cannabist-Company-Further-Extends-Forbearance-Agreement-With-Senior-Noteholders 2026-02-28T01:51:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T01:51:00.000Z The Cannabist Company Further Extends Forbearance Agreement With Senior Noteholders CBST,CBSTF https://mms.businesswire.com/media/20260227334210/en/2733995/21/TCC_Logo_Horz.jpg https://www.businesswire.com/news/home/20260227374991/en/KIRIN-HYOKETSU-Expands-into-U.S.-RTD-Market-with-Local-Production 2026-02-28T01:31:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T01:31:00.000Z KIRIN HYOKETSU Expands into U.S. RTD Market with Local Production 2503 https://mms.businesswire.com/media/20260227374991/en/2733211/21/HYOKETSU.jpg https://www.businesswire.com/news/home/20260227649072/en/REMINDER-Coreweave-Inc.-Investors-With-Significant-Losses-Must-Act-By-March-13-2026 2026-02-28T01:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T01:00:00.000Z REMINDER: Coreweave, Inc. Investors With Significant Losses Must Act By March 13, 2026 CRWV https://mms.businesswire.com/media/20260227649072/en/774509/21/new_KM_logo.jpg https://www.businesswire.com/news/home/20260227265237/en/CWH-INVESTOR-ALERT-Kirby-McInerney-LLP-Investigates-Potential-Claims-Involving-Camping-World-Holdings-Inc. 2026-02-28T01:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T01:00:00.000Z CWH INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Camping World Holdings, Inc. CWH https://www.businesswire.com/news/home/20260227314794/en/EPAM-SYSTEMS-INC.-INVESTOR-ALERT-Kirby-McInerney-LLP-Announces-Investigation-Into-Potential-Securities-Fraud 2026-02-28T01:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T01:00:00.000Z EPAM SYSTEMS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud EPAM https://www.businesswire.com/news/home/20260227486576/en/Biocytogen-Announces-Clinical-Milestone-with-First-Patient-Dosed-in-Phase-1-Trial-of-IDEAYAs-First-in-Class-B7H3PTK7-Bispecific-TOP1-ADC-IDE034 2026-02-28T00:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T00:00:00.000Z Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 688796,02315 https://mms.businesswire.com/media/20260227486576/en/2036944/21/Biocytogen_Logo_1080x1080px.jpg https://www.businesswire.com/news/home/20260227206909/en/Biocytogen-Announces-Clinical-Milestone-with-First-Patient-Dosed-in-Phase-1-Trial-of-IDEAYAs-First-in-Class-B7H3PTK7-Bispecific-TOP1-ADC-IDE034 2026-02-28T00:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-02-28T00:00:00.000Z Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 688796,02315 https://mms.businesswire.com/media/20260227206909/en/2733203/21/Logo_of_Biocytogen_on_Business_wire.jpg https://www.businesswire.com/news/home/20260227146095/zh-CN 2026-02-28T00:00:00.000Z weekly 0.5 Business Wire zh-CN PressRelease 2026-02-28T00:00:00.000Z 百奥赛图宣布达成重要临床里程碑，合作伙伴IDEAYA启动双抗ADC IDE034 I期临床并完成首例患者给药 688796,02315 https://mms.businesswire.com/media/20260227146095/zh-CN/2733203/21/Logo_of_Biocytogen_on_Business_wire.jpg